Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase II Double-Blind, Placebo-Controlled Study of the Reinforcing Effects of Alprazolam in Patients With Anxiety
This study has been completed.
Study NCT00004373   Information provided by Office of Rare Diseases (ORD)
First Received: October 18, 1999   Last Updated: June 23, 2005   History of Changes

October 18, 1999
June 23, 2005
March 1997
 
 
 
Complete list of historical versions of study NCT00004373 on ClinicalTrials.gov Archive Site
 
 
 
Phase II Double-Blind, Placebo-Controlled Study of the Reinforcing Effects of Alprazolam in Patients With Anxiety
 

OBJECTIVES: I. Determine whether the benzodiazepine alprazolam reinforces self-medication behavior in anxious patients with varying histories of using other drugs.

II. Establish outpatient methods for the study of self-medication and drug reinforcement in patients vulnerable to prescription drug abuse or dependence.

III. Evaluate the influence of alcohol and other non-prescription drug use as determinants of vulnerability in these patients.

IV. Identify personality, attitudinal, or other variables that might predict different patterns of self-medication.

V. Assess the effects of cognitive-behavioral therapy on alprazolam self-medication.

PROTOCOL OUTLINE: This protocol involves different experiments examining self-medication with anxiolytic medications in selected patients, and cognitive-behavioral therapy for anxiety. Capsules are color coded and taken under double-blind conditions. Compliance is monitored with the Medication Event Monitoring System, which automatically registers the date and time each bottle is opened.

The physician directs therapy administration, using some combination of the following: blind choice test, antianxiety agent(s), placebo, and cognitive-behavioral therapy.

Phase II
Interventional
Treatment
  • Anxiety Disorder
  • Panic Disorder
Drug: alprazolam
 
Roache JD, Stanley MA, Creson DR, Shah NN, Meisch RA. Alprazolam-reinforced medication use in outpatients with anxiety. Drug Alcohol Depend. 1997 May 2;45(3):143-55.

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
80
March 2001
 

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

  • Primary diagnosis of generalized anxiety or panic disorder Determined by Structured Clinical Interview for DSM IV
  • Hamilton Anxiety Scale (HAM-A) score at least 14 AND Profile of Mood States (POMS) tension/anxiety scale score at least 20
  • Concurrent diagnoses allowed: Mild to moderate agoraphobia Simple or social phobias Secondary unipolar affective disorders
  • No current substance abuse, dependence, or substance abuse treatment Drug-free urine sample required
  • No history of other primary Axis I diagnosis other than tobacco dependence

--Prior/Concurrent Therapy--

  • No prior formalized non-drug therapy for anxiety disorder
  • No concurrent prescription psychoactive medication
  • No history of benzodiazepine dependence

--Patient Characteristics--

  • Age: 18 to 50
  • Other: Medically healthy Negative pregnancy test required No occupational requirement to work in hazardous situations
Both
18 Years to 50 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00004373
 
199/11960, UTHSC-92120
National Institute on Drug Abuse (NIDA)
University of Texas
Study Chair: John D. Roache University of Texas
Office of Rare Diseases (ORD)
May 2003

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP